|
|
 Spot high risk patients sooner
Earlier answers for silent liver disease: practical steps and testing pathways for care teams.
Your quick guide to early risk assessment and NIT use
|
|
MASLD and MASH* are growing public health concerns. Our latest eBook, Unmasking a Silent Epidemic, summarizes current MASLD and MASH evidence, clarifies where noninvasive prognostic testing, such as the ELF® Test, fits in care pathways, and offers practical steps for earlier risk assessment. Written for laboratory and clinical leaders overseeing testing, quality, and integration across core, reference, and pathology services, this resource enables more proactive liver disease management.
This eBook highlights three key elements that provide insight into:
- The epidemiology and clinical impact of MASLD and MASH
- Current approaches for effective patient management
- Growing trends of noninvasive testing and evidence-based outcomes
Lead with evidence, not guesswork. Access the comprehensive eBook and gain a practical framework for earlier risk assessment and smarter liver disease management.
|
|
| *Formerly known as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). |
|
|
|
 
|
|
|
| About this email: SmartBrief will occasionally
send emails from our business partners promoting products and services likely to
be of interest to our readers. The content of these messages does not necessarily reflect
the view of SmartBrief or its association partners. |
|
|
|
|
| Copyright © 2025 SmartBrief. All Rights Reserved. A division of Future US LLC. |
| Full 7th Floor, 130 West 42nd Street, New York, NY, 10036. |
|
|
|
